551. A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–June 2025
Eine multistaatliche Untersuchung schwerer unerwünschter Ereignisse, einschließlich Todesfällen, nach Ceftriaxon-Injektionen, September 2024–Juni 2025
Open Forum Infectious Diseases · 11.01.2026 · 13 (Supplement_1)
DOI: 10.1093/ofid/ofaf695.024 ↗Auf einen Blick
Nach Meldungen schwerer unerwünschter Ereignisse nach Ceftriaxon-Injektionen wurden 26 Fälle untersucht, darunter 12 Todesfälle. Ein gemeinsamer Auslöser oder ein Bezug zu einem bestimmten Produkt wurde nicht gefunden.
Fragestellung
Welche schweren unerwünschten Ereignisse, einschließlich Todesfällen, traten nach Ceftriaxon-Gabe in den USA auf, und gibt es Hinweise auf eine gemeinsame Ursache?
Methode
CDC-Nachuntersuchung gemeldeter Fälle nach Ceftriaxon-Gabe; Definition: Tod oder Reanimation innerhalb von 6 Stunden nach Gabe in nicht-ICU-Settings ohne andere erkennbare Ursache; Daten von Gesundheitsbehörden und FDA-Produktprüfungen.
Ergebnisse
26 Fälle aus 22 Einrichtungen in 15 Bundesstaaten; 12 Todesfälle. 69 % (n=18) waren anaphylaxie-typisch. FDA-Tests von Ceftriaxon und Lidocain-Verdünnungsmittel zeigten keine Hinweise auf Manipulation, Verfälschung oder Qualitätsprobleme.
Schlussfolgerung der Autor:innen
Schwere unerwünschte Ereignisse, einschließlich Todesfällen, können nach Ceftriaxon auftreten. Die Untersuchung fand keine gemeinsame Ursache und keinen Zusammenhang mit einem bestimmten Ceftriaxon-Produkt.
Kernaussagen
- 26 Fälle, darunter 12 Todesfälle
- 69 % der Fälle waren anaphylaxie-typisch
- Kein Hinweis auf eine gemeinsame Produktursache
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 11.01.2026. Verfasst von Rebecca Pierce und 39 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Wednesday, October 22, 2025: 11:30 AM Background: Serious adverse events (SAEs) related to ceftriaxone, a widely used cephalosporin antibiotic, are considered rare. After a 2024 SAE cluster in Alabama, the Centers for Disease Control and Prevention (CDC), with state/local partners and the US Food and Drug Administration (FDA), conducted a nationwide investigation of SAEs, including deaths, among patients who received ceftriaxone.Table.Clinical summary of serious adverse event cases (n=26), September 2024–June 2025Abbreviations: SAE: serious adverse event, ACH: acute care hospital, ED: emergency department, OP: outpatient clinic, F: female, M: male, Pt: patient (used when sex not reported); NR: not reported, NOS: not otherwise specified, EKG: electrocardiogram, PEA: pulseless electrical activity, IV: intravenous, IM: intramuscular, N/A: not applicable, PMH: past medical history, CA: cancer, CAD: coronary artery disease, CHF: congestive heart failure, CKD/ESRD: chronic kidney disease or end stage renal disease; COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, HTN: hypertension, HLD: hyperlipidemia, dx: disease CPR: cardiopulmonary resuscitation.Figure 1a-b.Epidemic curve: Frequency of reported serious adverse event cases following ceftriaxone administration from September 2024 to June 2025, by event month and US region (a) or ceftriaxone manufacturer (b), n=26Figure includes SAEs meeting CDC case definition: Adverse events following injectable ceftriaxone exposure, occurring after September 1, 2024, which: 1) occurred within 6 hours after receipt of injectable ceftriaxone in a non-ICU setting, 2) resulted in death or required cardiopulmonary resuscitation (CPR), and 3) were not attributed by the treating provider(s) to a cause other than ceftriaxone administration (such as known infection, other underlying medical condition, or exposure to a medication or medical product other than ceftriaxone). Figure 1a (left) displays epidemic curve by US Census Bureau region, reflecting case-patient state of residence. Southern region includes AL, AR, DC, DE, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV. Figure 1b (right) displays epidemic curve by the ceftriaxone product reported as administered to case-patient or present in the facility at the time of adverse event. Abbreviations: NR: not reported, US: United States. (R Core Team, 2024).
Methods
CDC issued a national call for cases, defined as death or cardiopulmonary resuscitation within 6 hours of ceftriaxone receipt in non-intensive care settings without other apparent cause, occurring after Sep 1, 2024. Health departments collected clinical data for analysis at CDC. We further classified cases as anaphylaxis-type if determined by treating provider to be allergic or if involved two or more of: hypotension, respiratory compromise, cutaneous manifestations, and gastrointestinal symptoms. For SAEs reported Dec 2024-Jan 2025, FDA collected available ceftriaxone/diluent for testing and requested internal product investigations by manufacturers.Figure 2.Medications (other than ceftriaxone) prescribed proximal and prior to serious adverse event, by individual case-patient, n=23Abbreviations: ARB: angiotensin receptor blocker, ACE: angiotensin-converting enzyme, NSAID: non-steroidal anti-inflammatory drugs.
Results
We report 26 cases (65% outpatient; 35% inpatient), including 12 deaths, from 22 healthcare facilities across 15 states from Sep 1, 2024 to Jun 30, 2025 (Figure 1a). Case-patients had a median age of 70 years (IQR: 60-81) and received 1g (n=15, 58%), 2g (n=9, 35%), or unspecified (n=2, 7%) ceftriaxone doses via intravenous (IV) push (n=15, 58%), IV infusion (n=9, 35%), or intramuscular injection (n=2, 7%). Presentations varied (Table); 69% (n=18) were anaphylaxis-type. Prior ceftriaxone exposure (n=16, 62%), cardiac comorbidities (n=20, 77%), and/or concurrent use of antihypertensives (n=17, 65%, Figure 2) were common. Product exposures included 22 lots from 6 ceftriaxone manufacturers (Figure 1b). FDA testing of ceftriaxone (5 lots, 4 manufacturers) and lidocaine diluent (3 lots, 2 manufacturers) found no evidence of tampering, adulteration, endotoxin, or purity/potency issues. Manufacturers (n=4) did not report product anomalies.
Conclusion
SAEs, including deaths, can occur after ceftriaxone use. This investigation did not identify a common-source etiology, nor a link to a specific ceftriaxone product. Providers in all settings should monitor for SAEs, including anaphylaxis, and report to the FDA MedWatch Program. Disclosures: All Authors: No reported disclosures
Zitieren
APA
Pierce, R., Agarwal, R., Kayira, D., Lyles, J. L., Sivilus, M., Morrison, M. A., Stubblefield, A. W., Roderick, M., Landers, K., Harris, S., Dulski, T., Garner, K., Bhattarai, R., Stoltey, J., Biehle, L., Czaja, C. A., Hoffner, J. T., Charles, A., Wagner, J., …, & Adre, C. (2026). 551. A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–June 2025. Open Forum Infectious Diseases, 13(Supplement_1). https://doi.org/10.1093/ofid/ofaf695.024
Vancouver
Pierce R, Agarwal R, Kayira D, Lyles JL, Sivilus M, Morrison MA, et al. 551. A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–June 2025. Open Forum Infectious Diseases. 2026;13(Supplement_1). doi:10.1093/ofid/ofaf695.024
BibTeX
@article{Pierce2026,
author = {Pierce, Rebecca and Agarwal, Radhika and Kayira, Dumbani and Lyles, Jennifer Lind and Sivilus, Maribeth and Morrison, Melissa A and Stubblefield, Andrew W and Roderick, Melanie and Landers, Karen and Harris, Scott and Dulski, Theresa and Garner, Kelley and Bhattarai, Rachana and Stoltey, Juliet and Biehle, Lauren and Czaja, Christopher A and Hoffner, Joshua T and Charles, Argentina and Wagner, JoAnna and Gulley, Trent and Beeman, Haley and Thoroughman, Douglas A and Curran, Michael J and Flinchum, Andrea H and Salinas, Andrea and Lee, Grace and Moore, Riley and Brennan, Brenda M and Patel, Gargi and Mehr, Jason and Tran, Dat and Breitenstein, Liz and Sinkevitch, Jenna N and Tressler, Stacy and Kinsey, Cara Bicking and Tori, Marco and Wilson, Christopher and Godwin, Simone and Miller, Malakai and Adre, Cullen},
title = {551. A Multistate Investigation of Serious Adverse Events, Including Deaths, Following Ceftriaxone Injections, September 2024–June 2025},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {Supplement_1},
doi = {10.1093/ofid/ofaf695.024}
}
EUVIMED